{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T15:57:37Z","timestamp":1790611057629,"version":"4.1.0"},"reference-count":199,"publisher":"JMIR Publications Inc.","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Med Internet Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Gaps in pharmaceutical governance could widen with the adoption of AI, even as AI promises better pharmacovigilance in low-income countries (LICs). While advanced regulatory systems like Australia\u2019s are integrating AI into pharmaceutical governance, LICs with underdeveloped regulatory capabilities, such as South Sudan, lag behind. The potential divergence disorients the World Health Organization\u2019s \u201cMedicine Without Harm\u201d agenda and effective global pharmacovigilance. Moreover, evolving global governance initiatives, including the newly established United Nations scientific panel on AI, may be hampered by this global divergence in capabilities. This makes 3 critical interrelated questions: what are the moral trade-offs in the introduction of AI in health care, what power dynamics impact the introduction of AI into health systems, and how could AI be used for pharmacovigilance in LICs? This viewpoint aims at informing global policies and regulations on AI in pharmacovigilance. It uses clinical, policy, and regulatory practitioner insights to synthesize evidence on the ethical, economic, and clinical contours of AI in pharmacovigilance. It contrasts the high-income context of Australia with the low-income context of South Sudan and shows that national capabilities are instrumental for institutionalizing global practice. It identifies current ethical challenges with applying AI and digital health, which straddle epistemic, normative, and metaethical domains, such as misguidance, cultural devaluation, and trust deficit. These filter into demerits observed with current applications of AI to pharmacovigilance, from the detection of adverse drug events and adverse drug reactions to the simulation of clinical trials. The merits of current applications are multiple and depend on data quality, ranging from the detection of adverse drug reactions to real-time surveillance of medical errors and predictive application to population risk quantification of adverse drug events. The widening gaps in global capabilities amid rapid evolution of AI suggest the need for inclusive global governance in the early stages, especially because AI may be deterministic and effects may not be retrospectively surmountable. The viewpoint also assesses the sufficiency of current evaluation frameworks, noting that health economic models currently lag in capturing gains and losses from the adoption of AI in health systems, digital health frameworks are largely retrospective and overlook sociopolitical and financial contexts, and influential service-oriented frameworks for health systems overlook outcomes. It observes that, although AI could be harnessed across the breadth of the pharmaceutical system, effective evaluation of potential risks is hampered by upstream decisions in software development and procurement, which preclude aspects of subsequent application. This introduces inscrutability and weakens clinicians\u2019 role in risk adjudication, which may worsen with nonrepresentative evolution of AI. Using these insights and a case study on the low-income context of South Sudan, the viewpoint commends an integrated health systems framework and country-level investments in infrastructure and regulatory capabilities as requisites for effective global governance and equitable use of AI in pharmacovigilance.<\/jats:p>","DOI":"10.2196\/96374","type":"journal-article","created":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T15:25:12Z","timestamp":1790609112000},"page":"e96374-e96374","source":"Crossref","is-referenced-by-count":0,"title":["Governing AI for Pharmacovigilance in Low-Income Countries: Systems Perspective"],"prefix":"10.2196","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8454-7211","authenticated-orcid":false,"given":"Garang Majok","family":"Dut","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1010","published-online":{"date-parts":[[2026,9,28]]},"reference":[{"issue":"2","key":"R1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjgh-2019-001912","article-title":"Addressing the challenges of regulatory systems strengthening in small states","volume":"5","author":"Preston","journal-title":"BMJ Glob Health"},{"issue":"1","key":"R2","doi-asserted-by":"publisher","DOI":"10.1080\/20523211.2024.2375267","article-title":"Prevalence of substandard, falsified, unlicensed and unregistered medicine and its associated factors in Africa: a systematic review","volume":"17","author":"Asrade Mekonnen","journal-title":"J Pharm Policy Pract"},{"issue":"3","key":"R3","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1001\/jama.2024.21451","article-title":"FDA perspective on the regulation of artificial intelligence in health care and biomedicine","volume":"333","author":"Warraich","journal-title":"JAMA"},{"key":"R4","unstructured":"Russell S Norvig P . Artificial Intelligence: A Modern Approach. 4th ed. Pearson; 2020. ISBN: 9780134610993"},{"key":"R5","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2019.05.066","article-title":"New technologies, new disparities: the intersection of electronic health and digital health literacy","volume":"292","author":"Smith","journal-title":"Int J Cardiol"},{"issue":"6","key":"R6","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1016\/j.mjafi.2025.08.010","article-title":"Artificial intelligence in simulation-based training for health professions education: navigating the rabbit hole","volume":"81","author":"Negi","journal-title":"Med J Armed Forces India"},{"issue":"6","key":"R7","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1007\/s40290-018-0251-9","article-title":"Training augmented intelligent capabilities for pharmacovigilance: applying deep-learning approaches to individual case safety report processing","volume":"32","author":"Abatemarco","journal-title":"Pharmaceut Med"},{"issue":"6","key":"R8","doi-asserted-by":"publisher","DOI":"10.2196\/35053","article-title":"Emerging artificial intelligence-empowered mHealth: scoping review","volume":"10","author":"Bhatt","journal-title":"JMIR Mhealth Uhealth"},{"key":"R9","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2024.106938","article-title":"Artificial intelligence-driven pharmaceutical industry: a paradigm shift in drug discovery, formulation development, manufacturing, quality control, and post-market surveillance","volume":"203","author":"Huanbutta","journal-title":"Eur J Pharm Sci"},{"issue":"4","key":"R10","doi-asserted-by":"publisher","DOI":"10.3390\/bioengineering12040363","article-title":"Advanced artificial intelligence technologies transforming contemporary pharmaceutical research","volume":"12","author":"Kumar","journal-title":"Bioengineering (Basel)"},{"issue":"9","key":"R11","doi-asserted-by":"publisher","first-page":"103700","DOI":"10.1016\/j.drudis.2023.103700","article-title":"Artificial intelligence in pharmaceutical regulatory affairs","volume":"28","author":"Patil","journal-title":"Drug Discov Today"},{"issue":"8","key":"R12","doi-asserted-by":"publisher","first-page":"104058","DOI":"10.1016\/j.drudis.2024.104058","article-title":"50 shades of AI in regulatory science","volume":"29","author":"Tong","journal-title":"Drug Discov Today"},{"issue":"12","key":"R13","doi-asserted-by":"publisher","first-page":"1991","DOI":"10.1016\/j.clinthera.2018.07.012","article-title":"Pharmacovigilance: an overview","volume":"40","author":"Beninger","journal-title":"Clin Ther"},{"key":"R14","unstructured":"Pharmacovigilance: ensuring the safe use of medicines. World Health Organization; 2004. URL: https:\/\/www.who.int\/publications\/i\/item\/WHOEDM2004.8 [Accessed 09-09-2026]"},{"issue":"Suppl 4","key":"R15","doi-asserted-by":"publisher","DOI":"10.1136\/bmjgh-2022-008759","article-title":"Usage of social media in epidemic intelligence activities in the WHO, Regional Office for the Eastern Mediterranean","volume":"7","author":"Abbas","journal-title":"BMJ Glob Health"},{"key":"R16","unstructured":"WHO upgrades its public health intelligence system to boost global health security. World Health Organization. 2025. URL: https:\/\/www.who.int\/news\/item\/13-10-2025-who-upgrades-its-public-health-intelligence-system-to-boost-global-health-security [Accessed 09-09-2026]"},{"issue":"5","key":"R17","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1007\/s40290-022-00441-z","article-title":"The use of artificial intelligence in pharmacovigilance: a systematic review of the literature","volume":"36","author":"Salas","journal-title":"Pharmaceut Med"},{"issue":"1","key":"R18","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1057\/s41599-025-04564-x","article-title":"Artificial intelligence in the COVID-19 pandemic: balancing benefits and ethical challenges in China\u2019s response","volume":"12","author":"Ding","journal-title":"Humanit Soc Sci Commun"},{"issue":"5","key":"R19","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1007\/s40264-022-01153-8","article-title":"Validation of artificial intelligence to support the automatic coding of patient adverse drug reaction reports, using nationwide pharmacovigilance data","volume":"45","author":"Martin","journal-title":"Drug Saf"},{"key":"R20","unstructured":"FDA announces completion of first AI-assisted scientific review pilot and aggressive agency-wide AI rollout timeline. US Food and Drug Administration. 2025. URL: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-announces-completion-first-ai-assisted-scientific-review-pilot-and-aggressive-agency-wide-ai [Accessed 09-09-2026]"},{"issue":"1","key":"R21","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1111\/1468-0009.70001","article-title":"The political economy of the World Health Organization model lists of essential medicines","volume":"103","author":"Jenei","journal-title":"Milbank Q"},{"issue":"5","key":"R22","doi-asserted-by":"publisher","first-page":"295","DOI":"10.15171\/ijhpm.2015.55","article-title":"Pharmacovigilance in India, Uganda and South Africa with reference to WHO\u2019s minimum requirements","volume":"4","author":"Maigetter","journal-title":"Int J Health Policy Manag"},{"issue":"3","key":"R23","doi-asserted-by":"publisher","first-page":"127","DOI":"10.4314\/ssmj.v18i3.8","article-title":"Review Article: Eyes in the sky: considerations for a teleophthalmology service in South Sudan","volume":"18","author":"Dut","journal-title":"South Sudan Med J"},{"issue":"2","key":"R24","doi-asserted-by":"publisher","first-page":"78","DOI":"10.4314\/ssmj.v18i2.5","article-title":"Underdeveloped but essential: findings from a survey of private pharmaceutical firms in South Sudan","volume":"18","author":"Dut","journal-title":"South Sudan Med J"},{"issue":"6","key":"R25","doi-asserted-by":"publisher","first-page":"186","DOI":"10.18773\/austprescr.2024.056","article-title":"Pharmacovigilance in Australia: how do adverse event reports from clinicians contribute to medicine and vaccine safety?","volume":"47","author":"Greenbaum","journal-title":"Aust Prescr"},{"issue":"8","key":"R26","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1007\/s40264-020-00940-5","article-title":"Detecting medicine safety signals using prescription sequence symmetry analysis of a national prescribing data set","volume":"43","author":"King","journal-title":"Drug Saf"},{"issue":"8","key":"R27","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1007\/s40264-020-00939-y","article-title":"A feasibility study of drug-drug interaction signal detection in regular pharmacovigilance","volume":"43","author":"Hult","journal-title":"Drug Saf"},{"issue":"8","key":"R28","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1002\/pds.3780","article-title":"Prescription sequence symmetry analysis: assessing risk, temporality, and consistency for adverse drug reactions across datasets in five countries","volume":"24","author":"Pratt","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"7","key":"R29","doi-asserted-by":"publisher","DOI":"10.3390\/healthcare13070817","article-title":"Artificial intelligence-based software as a medical device (AI-SaMD): a systematic review","volume":"13","author":"Ebad","journal-title":"Healthcare (Basel)"},{"issue":"20","key":"R30","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp2504926","article-title":"Judicial invalidation of the FDA\u2019s laboratory-developed test rule - legal and public health consequences","volume":"392","author":"Sachs","journal-title":"N Engl J Med"},{"issue":"2","key":"R31","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.jaad.2023.04.011","article-title":"Racial and ethnic underrepresentation in dermatology clinical trials","volume":"89","author":"Mineroff","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"R32","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1016\/j.ygyno.2020.03.002","article-title":"Minority participation in phase 1 gynecologic oncology clinical trials: three decades of inequity","volume":"157","author":"Awad","journal-title":"Gynecol Oncol"},{"issue":"6","key":"R33","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph19063313","article-title":"Building the momentum for a stronger pharmaceutical system in Africa","volume":"19","author":"Ussai","journal-title":"Int J Environ Res Public Health"},{"issue":"10","key":"R34","doi-asserted-by":"publisher","first-page":"722","DOI":"10.2471\/BLT.24.292359","article-title":"WHO model list of essential medicines: visions for the future","volume":"102","author":"Piggott","journal-title":"Bull World Health Organ"},{"issue":"11","key":"R35","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1093\/eurheartj\/ehac810","article-title":"Improving representativeness in trials: a call to action from the Global Cardiovascular Clinical Trialists Forum","volume":"44","author":"Filbey","journal-title":"Eur Heart J"},{"issue":"1","key":"R36","doi-asserted-by":"publisher","DOI":"10.1186\/s12939-018-0748-6","article-title":"Barriers for conducting clinical trials in developing countries - a systematic review","volume":"17","author":"Alemayehu","journal-title":"Int J Equity Health"},{"issue":"7","key":"R37","doi-asserted-by":"publisher","DOI":"10.1002\/alz.70460","article-title":"Synthetic control methods for n-of-1 and parallel-group trials in Alzheimer\u2019s disease: a proof-of-concept study using the I-CONECT","volume":"21","author":"Wu","journal-title":"Alzheimers Dement"},{"issue":"5","key":"R38","doi-asserted-by":"publisher","first-page":"100851","DOI":"10.1016\/j.landig.2025.01.007","article-title":"Digital twins, synthetic patient data, and in-silico trials: can they empower paediatric clinical trials?","volume":"7","author":"Pammi","journal-title":"Lancet Digit Health"},{"issue":"5","key":"R39","doi-asserted-by":"publisher","DOI":"10.1093\/bib\/bbaf492","article-title":"Benchmarking large language models for genomic knowledge with GeneTuring","volume":"26","author":"Shang","journal-title":"Brief Bioinform"},{"issue":"3","key":"R40","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/j.healthpol.2014.05.005","article-title":"Managed entry agreements for pharmaceuticals in Australia","volume":"117","author":"Vitry","journal-title":"Health Policy"},{"issue":"12","key":"R41","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1007\/s40273-017-0559-4","article-title":"The implementation of managed entry agreements in Central and Eastern Europe: findings and implications","volume":"35","author":"Ferrario","journal-title":"Pharmacoeconomics"},{"issue":"5","key":"R42","doi-asserted-by":"publisher","first-page":"2333","DOI":"10.19082\/2333","article-title":"Components that affect the implementation of health services\u2019 strategic purchasing: a comprehensive review of the literature","volume":"8","author":"Bastani","journal-title":"Electron Physician"},{"issue":"3","key":"R43","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1111\/1468-0009.12471","article-title":"Power and purchasing: why strategic purchasing fails","volume":"98","author":"Greer","journal-title":"Milbank Q"},{"issue":"1","key":"R44","doi-asserted-by":"publisher","first-page":"40","DOI":"10.34172\/hpp.2023.05","article-title":"Access to medicines through global health diplomacy","volume":"13","author":"Chattu","journal-title":"Health Promot Perspect"},{"issue":"9299","key":"R45","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(01)07212-9","article-title":"Usefulness of foreign aid for health care in less-developed countries","volume":"358","author":"Adelman","journal-title":"Lancet"},{"issue":"9314","key":"R46","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(02)08303-4","article-title":"Generic medicines are not substandard medicines","volume":"359","author":"Ford","journal-title":"Lancet"},{"issue":"4","key":"R47","doi-asserted-by":"publisher","first-page":"288","DOI":"10.4103\/0972-9062.302030","article-title":"Global scenario of counterfeit antimalarials: a potential threat","volume":"56","author":"Arora","journal-title":"J Vector Borne Dis"},{"issue":"10001","key":"R48","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1016\/S0140-6736(15)00394-3","article-title":"Rise in online pharmacies sees counterfeit drugs go global","volume":"386","author":"Clark","journal-title":"The Lancet"},{"key":"R49","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2021.100219","article-title":"Impact of the European Union on access to medicines in low- and middle-income countries: a scoping review","volume":"9","author":"Perehudoff","journal-title":"Lancet Reg Health Eur"},{"key":"R50","unstructured":"Council conclusions on the EU role in global health. Council of the European Union; 2010. URL: https:\/\/www.consilium.europa.eu\/uedocs\/cms_data\/docs\/pressdata\/en\/foraff\/114352.pdf [Accessed 09-09-2026]"},{"issue":"2","key":"R51","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1000411","article-title":"Registering new drugs for low-income countries: the African challenge","volume":"8","author":"Moran","journal-title":"PLoS Med"},{"issue":"3","key":"R52","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1080\/17512433.2020.1724782","article-title":"The European Medicines Agency facilitates access to medicines in low- and middle-income countries","volume":"13","author":"Cavaller Bellaubi","journal-title":"Expert Rev Clin Pharmacol"},{"key":"R53","unstructured":"Christophe P Sandrine C . Analysis of the quality assurance and pharmaceutical procurement policies of a sample of European donors. Institute of Tropical Medicine; 2020. URL: https:\/\/www.itg.be\/en\/attachment\/9b8955ef-6d8c-468b-9c06-8c90d3a9599e\/analysis-of-the-quality-assurance-and-pharmaceutical-procurement-policies-of-a-sample-of-european-donors.pdf [Accessed 09-09-2026]"},{"issue":"4","key":"R54","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1353\/jod.2023.a907695","article-title":"The authoritarian data problem","volume":"34","author":"Yang","journal-title":"J Democr"},{"key":"R55","volume":"620","author":"Hutson","journal-title":"Nature"},{"key":"R56","doi-asserted-by":"publisher","DOI":"10.1038\/d41586-026-00542-8","article-title":"UN creates new scientific AI advisory panel: what will it do?","author":"Gibney","journal-title":"Nature"},{"issue":"8","key":"R57","doi-asserted-by":"publisher","first-page":"546","DOI":"10.2471\/BLT.17.198002","article-title":"The third global patient safety challenge: tackling medication-related harm","volume":"95","author":"Sheikh","journal-title":"Bull World Health Organ"},{"issue":"6","key":"R58","doi-asserted-by":"publisher","first-page":"373","DOI":"10.4103\/ijp.IJP_814_19","article-title":"Artificial intelligence in pharmacovigilance: practical utility","volume":"51","author":"Murali","journal-title":"Indian J Pharmacol"},{"key":"R59","unstructured":"Medication without harm \u2013 WHO global patient safety challenge: Australia\u2019s response. Australian Commission on Safety and Quality in Health Care (ACSQHC); 2024. URL: https:\/\/www.safetyandquality.gov.au\/sites\/default\/files\/resources\/attachments\/\/status_report_-_medication_without_harm_who_global_patient_safety_challenge_-_australias_response.pdf [Accessed 10-09-2026]"},{"key":"R60","unstructured":"The WHO Programme for International Drug Monitoring. World Health Organization. 2025. URL: https:\/\/www.who.int\/teams\/regulation-prequalification\/regulation-and-safety\/pharmacovigilance\/networks\/pidm [Accessed 10-09-2026]"},{"key":"R61","unstructured":"VigiAccess. World Health Organization. 2025. URL: https:\/\/www.vigiaccess.org\/ [Accessed 10-09-2026]"},{"key":"R62","unstructured":"Minimum requirements for a functional pharmacovigilance system. World Health Organization; 2010. URL: https:\/\/cdn.who.int\/media\/docs\/default-source\/medicines\/pharmacovigilance\/pv_minimum_requirements_2010_2.pdf?sfvrsn=8bfdc82a_1 [Accessed 10-09-2026]"},{"issue":"7","key":"R63","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1080\/14740338.2023.2227091","article-title":"Will the future of pharmacovigilance be more automated?","volume":"22","author":"Salvo","journal-title":"Expert Opin Drug Saf"},{"issue":"3","key":"R64","doi-asserted-by":"publisher","first-page":"116","DOI":"10.4103\/picr.picr_290_23","article-title":"Artificial intelligence in pharmacovigilance - opportunities and challenges","volume":"15","author":"Desai","journal-title":"Perspect Clin Res"},{"issue":"2","key":"R65","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.pxur.2025.01.002","article-title":"Strengthening pharmaceutical management in a health centre in South Sudan through e-learning","volume":"9","author":"Le Bloc\u2019h","journal-title":"M\u00e9d Catastrophe Urg Collectives"},{"issue":"1","key":"R66","doi-asserted-by":"publisher","DOI":"10.1186\/s12939-022-01665-w","article-title":"The political economy of priority-setting for health in South Sudan: a case study of the health pooled fund","volume":"21","author":"Widdig","journal-title":"Int J Equity Health"},{"key":"R67","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2025.1708784","article-title":"Substandard and falsified medicines in Africa: healthcare systems challenges, supply chain issues, regulatory challenges and strategies to increase access to quality medicines","volume":"16","author":"Chabalenge","journal-title":"Front Pharmacol"},{"issue":"2","key":"R68","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1007\/s11948-017-9901-7","article-title":"Artificial intelligence and the \u201cGood Society\u201d: the US, EU, and UK approach","volume":"24","author":"Cath","journal-title":"Sci Eng Ethics"},{"issue":"3","key":"R69","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1007\/s44197-024-00228-2","article-title":"Current status of malaria control and elimination in Africa: epidemiology, diagnosis, treatment, progress and challenges","volume":"14","author":"Li","journal-title":"J Epidemiol Glob Health"},{"issue":"6","key":"R70","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1016\/S1473-3099(12)70064-6","article-title":"Poor-quality antimalarial drugs in southeast Asia and sub-Saharan Africa","volume":"12","author":"Nayyar","journal-title":"Lancet Infect Dis"},{"issue":"1","key":"R71","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0295956","article-title":"Substandard and falsified antimicrobials in selected East African countries: a systematic review","volume":"19","author":"Tegegne","journal-title":"PLoS One"},{"issue":"1","key":"R72","doi-asserted-by":"publisher","DOI":"10.1186\/s12889-020-08852-w","article-title":"Impact of substandard and falsified antimalarials in Zambia: application of the SAFARI model","volume":"20","author":"Jackson","journal-title":"BMC Public Health"},{"key":"R73","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2017.04.099","article-title":"Fighting fake medicines: first quality evaluation of cardiac drugs in Africa","volume":"243","author":"Antignac","journal-title":"Int J Cardiol"},{"issue":"2","key":"R74","doi-asserted-by":"publisher","first-page":"894","DOI":"10.4269\/ajtmh.20-0184","article-title":"Substandard and falsified antibiotics and medicines against noncommunicable diseases in western Cameroon and northeastern Democratic Republic of Congo","volume":"103","author":"Sch\u00e4fermann","journal-title":"Am J Trop Med Hyg"},{"issue":"4","key":"R75","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1586\/14787210.2015.1015990","article-title":"Falsified antimalarials: a minireview","volume":"13","author":"Chaccour","journal-title":"Expert Rev Anti Infect Ther"},{"issue":"8","key":"R76","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0217910","article-title":"The economic impact of substandard and falsified antimalarial medications in Nigeria","volume":"14","author":"Beargie","journal-title":"PLoS One"},{"issue":"2","key":"R77","doi-asserted-by":"publisher","first-page":"228","DOI":"10.4269\/ajtmh.22-0525","article-title":"Health, economic, and social impacts of substandard and falsified medicines in low-and middle-income countries: a systematic review of methodological approaches","volume":"109","author":"Salami","journal-title":"Am J Trop Med Hyg"},{"issue":"4","key":"R78","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2018.1662","article-title":"Prevalence and estimated economic burden of substandard and falsified medicines in low- and middle-income countries: a systematic review and meta-analysis","volume":"1","author":"Ozawa","journal-title":"JAMA Netw Open"},{"issue":"5","key":"R79","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.4269\/ajtmh.18-0334","article-title":"Modeling the economic impact of substandard and falsified antimalarials in the Democratic Republic of the Congo","volume":"100","author":"Ozawa","journal-title":"Am J Trop Med Hyg"},{"issue":"6","key":"R80","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.4269\/ajtmh.21-0450","article-title":"Assessing the impact of substandard and falsified antimalarials in Benin","volume":"106","author":"Bui","journal-title":"Am J Trop Med Hyg"},{"issue":"1","key":"R81","doi-asserted-by":"publisher","DOI":"10.1186\/s12936-018-2628-3","article-title":"Development of an agent-based model to assess the impact of substandard and falsified anti-malarials: Uganda case study","volume":"18","author":"Ozawa","journal-title":"Malar J"},{"issue":"1","key":"R82","doi-asserted-by":"publisher","DOI":"10.1186\/1475-2875-13-209","article-title":"The counterfeit anti-malarial is a crime against humanity: a systematic review of the scientific evidence","volume":"13","author":"Karunamoorthi","journal-title":"Malar J"},{"issue":"Supplement_3","key":"R83","doi-asserted-by":"publisher","first-page":"iii36","DOI":"10.1093\/heapol\/czz012","article-title":"Poor-quality antimalarials further health inequities in Uganda","volume":"34","author":"Evans","journal-title":"Health Policy Plan"},{"issue":"2","key":"R84","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1128\/CMR.00072-14","article-title":"Substandard\/counterfeit antimicrobial drugs","volume":"28","author":"Kelesidis","journal-title":"Clin Microbiol Rev"},{"issue":"1","key":"R85","doi-asserted-by":"publisher","first-page":"e40","DOI":"10.5301\/maapoc.0000008","article-title":"What\u2019s in a word? Falsified\/counterfeit\/fake medicines \u2013 the definitions debate","volume":"1","author":"Isles","journal-title":"Med Access Point Care"},{"issue":"1","key":"R86","doi-asserted-by":"publisher","DOI":"10.1186\/s12992-022-00826-4","article-title":"What is the impact of intellectual property rules on access to medicines? A systematic review","volume":"18","author":"Tenni","journal-title":"Global Health"},{"key":"R87","doi-asserted-by":"publisher","DOI":"10.1016\/j.socscimed.2021.114479","article-title":"Product patents and access to innovative medicines","volume":"291","author":"Dai","journal-title":"Soc Sci Med"},{"issue":"3","key":"R88","doi-asserted-by":"publisher","first-page":"185","DOI":"10.2471\/BLT.17.199364","article-title":"Medicine procurement and the use of flexibilities in the Agreement on Trade-Related Aspects of Intellectual Property Rights, 2001-2016","volume":"96","author":"\u2019t Hoen","journal-title":"Bull World Health Organ"},{"issue":"1","key":"R89","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1007\/s00216-010-3748-y","article-title":"Counterfeit drugs: analytical techniques for their identification","volume":"398","author":"Martino","journal-title":"Anal Bioanal Chem"},{"key":"R90","doi-asserted-by":"publisher","DOI":"10.1016\/j.glmedi.2024.100139","article-title":"Artificial intelligence and big data for pharmacovigilance and patient safety","volume":"3","author":"Shamim","journal-title":"J Med Surg Public Health"},{"issue":"13","key":"R91","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1001\/jama.2013.2376","article-title":"IOM: curbing fake drugs will require national tracking and global teamwork","volume":"309","author":"Kuehn","journal-title":"JAMA"},{"issue":"7659","key":"R92","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1038\/546474c","article-title":"Fight fake reagents with digital tools","volume":"546","author":"Gunasekera","journal-title":"Nature"},{"issue":"1003","key":"R93","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1136\/pgmj.2008.073213","article-title":"Spurious and counterfeit drugs: a growing industry in the developing world","volume":"85","author":"Gautam","journal-title":"Postgrad Med J"},{"issue":"5","key":"R94","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1080\/14740338.2017.1313227","article-title":"A review of existing and emerging digital technologies to combat the global trade in fake medicines","volume":"16","author":"Mackey","journal-title":"Expert Opin Drug Saf"},{"issue":"8","key":"R95","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1111\/j.1365-3156.2008.02106.x","article-title":"Substandard medicines in resource-poor settings: a problem that can no longer be ignored","volume":"13","author":"Caudron","journal-title":"Trop Med Int Health"},{"issue":"1","key":"R96","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-16674-x","article-title":"Knowledge graph prediction of unknown adverse drug reactions and validation in electronic health records","volume":"7","author":"Bean","journal-title":"Sci Rep"},{"issue":"1","key":"R97","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1007\/s40264-018-0764-x","article-title":"Adverse drug events detection in clinical notes by jointly modeling entities and relations using neural networks","volume":"42","author":"Dandala","journal-title":"Drug Saf"},{"issue":"1","key":"R98","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/s40264-018-0761-0","article-title":"MADEx: a system for detecting medications, adverse drug events, and their relations from clinical notes","volume":"42","author":"Yang","journal-title":"Drug Saf"},{"issue":"1","key":"R99","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1007\/s40264-018-0763-y","article-title":"Detecting adverse drug events with rapidly trained classification models","volume":"42","author":"Chapman","journal-title":"Drug Saf"},{"issue":"Suppl 5","key":"R100","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2164-12-S5-S11","article-title":"Predicting adverse side effects of drugs","volume":"12","author":"Huang","journal-title":"BMC Genomics"},{"key":"R101","doi-asserted-by":"publisher","DOI":"10.1016\/j.compbiomed.2015.11.005","article-title":"ARWAR: a network approach for predicting adverse drug reactions","volume":"68","author":"Rahmani","journal-title":"Comput Biol Med"},{"issue":"Suppl 21","key":"R102","doi-asserted-by":"publisher","DOI":"10.1186\/s12859-018-2544-0","article-title":"Predicting adverse drug reactions through interpretable deep learning framework","volume":"19","author":"Dey","journal-title":"BMC Bioinformatics"},{"issue":"4","key":"R103","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1007\/s12553-017-0179-1","article-title":"Google DeepMind and healthcare in an age of algorithms","volume":"7","author":"Powles","journal-title":"Health Technol (Berl)"},{"key":"R104","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbi.2025.104879","article-title":"Digital twins in increasing diversity in clinical trials: a systematic review","volume":"169","author":"Tubbs","journal-title":"J Biomed Inform"},{"issue":"12","key":"R105","doi-asserted-by":"publisher","DOI":"10.3390\/healthcare10122493","article-title":"Economics of artificial intelligence in healthcare: diagnosis vs. treatment","volume":"10","author":"Khanna","journal-title":"Healthcare (Basel)"},{"issue":"114","key":"R106","first-page":"10","volume":"35","author":"Kim","journal-title":"Community Eye Health"},{"issue":"85","key":"R107","first-page":"7","volume":"27","author":"Ravilla","journal-title":"Community Eye Health"},{"issue":"9","key":"R108","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1001\/jamaophthalmol.2019.2004","article-title":"Performance of a deep-learning algorithm vs manual grading for detecting diabetic retinopathy in India","volume":"137","author":"Gulshan","journal-title":"JAMA Ophthalmol"},{"key":"R109","doi-asserted-by":"publisher","DOI":"10.1016\/j.preteyeres.2020.100900","article-title":"Digital technology, tele-medicine and artificial intelligence in ophthalmology: a global perspective","volume":"82","author":"Li","journal-title":"Prog Retin Eye Res"},{"issue":"3","key":"R110","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1071\/AH21263","article-title":"Digital health to support primary care provision during a global pandemic","volume":"46","author":"Sturgiss","journal-title":"Aust Health Rev"},{"key":"R111","doi-asserted-by":"publisher","DOI":"10.1177\/20552076241297729","article-title":"Digital health implementation in Australia: a scientometric review of the research","volume":"10","author":"Krahe","journal-title":"Digit Health"},{"key":"R112","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijmedinf.2021.104483","article-title":"\u201cA decade\u2019s worth of work in a matter of days\u201d: the journey to telehealth for the whole population in Australia","volume":"151","author":"Hall Dykgraaf","journal-title":"Int J Med Inform"},{"key":"R113","doi-asserted-by":"publisher","DOI":"10.2196\/39384","article-title":"Use of general practitioner telehealth services during the COVID-19 pandemic in regional Victoria, Australia: retrospective analysis","volume":"25","author":"Savira","journal-title":"J Med Internet Res"},{"issue":"3","key":"R114","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1016\/j.jval.2021.12.009","article-title":"The value of artificial intelligence for healthcare decision making-lessons learned","volume":"25","author":"Whicher","journal-title":"Value Health"},{"issue":"3","key":"R115","first-page":"319","volume":"15","author":"Kenny","journal-title":"Aust Health Rev"},{"key":"R116","doi-asserted-by":"publisher","DOI":"10.1093\/heapol\/czs088","article-title":"Health systems, systems thinking and innovation","volume":"27 Suppl 4","author":"Atun","journal-title":"Health Policy Plan"},{"key":"R117","doi-asserted-by":"publisher","DOI":"10.1016\/j.socscimed.2023.116357","article-title":"Multi-stakeholder preferences for the use of artificial intelligence in healthcare: a systematic review and thematic analysis","volume":"338","author":"Vo","journal-title":"Soc Sci Med"},{"issue":"8","key":"R118","doi-asserted-by":"publisher","DOI":"10.1016\/S2589-7500(19)30193-1","article-title":"Google Health and the NHS: overcoming the trust deficit","volume":"1","author":"Morley","journal-title":"Lancet Digit Health"},{"key":"R119","doi-asserted-by":"publisher","DOI":"10.1038\/s41746-019-0155-4","article-title":"The \u201cinconvenient truth\u201d about AI in healthcare","volume":"2","author":"Panch","journal-title":"NPJ Digit Med"},{"issue":"1","key":"R120","doi-asserted-by":"publisher","DOI":"10.1186\/s12911-022-01858-x","article-title":"Electronic health record implementation and healthcare workers\u2019 work characteristics and autonomous motivation-a before-and-after study","volume":"22","author":"Veenstra","journal-title":"BMC Med Inform Decis Mak"},{"issue":"1","key":"R121","doi-asserted-by":"publisher","DOI":"10.1186\/s12911-023-02103-9","article-title":"Ethics and governance of trustworthy medical artificial intelligence","volume":"23","author":"Zhang","journal-title":"BMC Med Inform Decis Mak"},{"issue":"12","key":"R122","doi-asserted-by":"publisher","first-page":"695","DOI":"10.47102\/annals-acadmedsg.2023103","article-title":"Artificial intelligence in medicine: ethical, social and legal perspectives","volume":"52","author":"Sung","journal-title":"Ann Acad Med Singap"},{"issue":"6","key":"R123","doi-asserted-by":"publisher","first-page":"1977","DOI":"10.1093\/ia\/iiac226","article-title":"Virtual sovereignty? Private internet capital, digital platforms and infrastructural power in the United States","volume":"98","author":"Kelton","journal-title":"Int Aff"},{"key":"R124","doi-asserted-by":"publisher","DOI":"10.1016\/j.rcsop.2023.100346","article-title":"Artificial intelligence in the field of pharmacy practice: a literature review","volume":"12","author":"Chalasani","journal-title":"Explor Res Clin Soc Pharm"},{"key":"R125","doi-asserted-by":"publisher","DOI":"10.1016\/j.socscimed.2020.113172","article-title":"The ethics of AI in health care: a mapping review","volume":"260","author":"Morley","journal-title":"Soc Sci Med"},{"issue":"4","key":"R126","doi-asserted-by":"publisher","DOI":"10.1016\/j.patter.2022.100462","article-title":"The role of the African value of Ubuntu in global AI inclusion discourse: a normative ethics perspective","volume":"3","author":"Gwagwa","journal-title":"Patterns (N Y)"},{"issue":"7","key":"R127","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1111\/bioe.12885","article-title":"Evaluation of artificial intelligence clinical applications: detailed case analyses show value of healthcare ethics approach in identifying patient care issues","volume":"35","author":"Rogers","journal-title":"Bioethics"},{"issue":"1","key":"R128","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1108\/JICES-04-2022-0037","article-title":"The ethics of artificial intelligence, UNESCO and the African Ubuntu perspective","volume":"21","author":"van Norren","journal-title":"J Inf Commun Ethics Soc"},{"key":"R129","doi-asserted-by":"publisher","DOI":"10.1016\/j.compbiomed.2021.104660","article-title":"Mapping research strands of ethics of artificial intelligence in healthcare: a bibliometric and content analysis","volume":"135","author":"Saheb","journal-title":"Comput Biol Med"},{"issue":"5-6","key":"R130","doi-asserted-by":"publisher","first-page":"52","DOI":"10.17159\/sajs.2023\/14905","article-title":"Exploring perspectives of research ethics committee members on the governance of big data in sub-Saharan Africa","volume":"119","author":"Cengiz","journal-title":"S Afr J Sci"},{"issue":"1","key":"R131","doi-asserted-by":"publisher","DOI":"10.1186\/s12910-024-01044-w","article-title":"Research ethics and artificial intelligence for global health: perspectives from the global forum on bioethics in research","volume":"25","author":"Shaw","journal-title":"BMC Med Ethics"},{"issue":"1","key":"R132","doi-asserted-by":"publisher","DOI":"10.1186\/s12910-021-00577-8","article-title":"Artificial intelligence for good health: a scoping review of the ethics literature","volume":"22","author":"Murphy","journal-title":"BMC Med Ethics"},{"key":"R133","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbi.2015.11.004","article-title":"Crowdsourcing Twitter annotations to identify first-hand experiences of prescription drug use","volume":"58","author":"Alvaro","journal-title":"J Biomed Inform"},{"issue":"4","key":"R134","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1093\/jamia\/ocw180","article-title":"Deep learning for pharmacovigilance: recurrent neural network architectures for labeling adverse drug reactions in Twitter posts","volume":"24","author":"Cocos","journal-title":"J Am Med Inform Assoc"},{"issue":"3","key":"R135","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1093\/jamia\/ocu041","article-title":"Pharmacovigilance from social media: mining adverse drug reaction mentions using sequence labeling with word embedding cluster features","volume":"22","author":"Nikfarjam","journal-title":"J Am Med Inform Assoc"},{"issue":"9","key":"R136","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1016\/j.tips.2019.07.005","article-title":"Artificial intelligence for drug toxicity and safety","volume":"40","author":"Basile","journal-title":"Trends Pharmacol Sci"},{"issue":"6","key":"R137","doi-asserted-by":"publisher","DOI":"10.2196\/30137","article-title":"The use of social media in detecting drug safety-related new black box warnings, labeling changes, or withdrawals: scoping review","volume":"7","author":"Lee","journal-title":"JMIR Public Health Surveill"},{"issue":"10","key":"R138","doi-asserted-by":"publisher","first-page":"103539","DOI":"10.1016\/j.jbi.2020.103539","article-title":"Comparing deep learning architectures for sentiment analysis on drug reviews","volume":"110","author":"Col\u00f3n-Ruiz","journal-title":"J Biomed Inform"},{"issue":"4","key":"R139","doi-asserted-by":"publisher","first-page":"3123","DOI":"10.1177\/1460458219833102","article-title":"Automated classification of primary care patient safety incident report content and severity using supervised machine learning (ML) approaches","volume":"26","author":"Evans","journal-title":"Health Informatics J"},{"key":"R140","unstructured":"The Drug and Food Control Authority Act, 2012. Ministry of Justice, Republic of South Sudan; 2012. URL: https:\/\/extranet.who.int\/cpcd\/sites\/default\/files\/public_file_repository\/SSD_South-Sudan_The-Drug-and_Food-Control-Authority-Act_2012.pdf [Accessed 10-09-2026]"},{"issue":"3","key":"R141","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1111\/jep.13542","article-title":"Artificial intelligence methods for a Bayesian epistemology-powered evidence evaluation","volume":"27","author":"De Pretis","journal-title":"J Eval Clin Pract"},{"key":"R142","doi-asserted-by":"publisher","DOI":"10.3233\/SHTI190777","article-title":"Clinical safety incident taxonomy performance on C4.5 decision tree and random forest","volume":"266","author":"Gupta","journal-title":"Stud Health Technol Inform"},{"issue":"Suppl 13","key":"R143","doi-asserted-by":"publisher","DOI":"10.1186\/s12859-016-1220-5","article-title":"Leveraging graph topology and semantic context for pharmacovigilance through twitter-streams","volume":"17","author":"Eshleman","journal-title":"BMC Bioinformatics"},{"issue":"10","key":"R144","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1002\/pds.4857","article-title":"Comparison of text processing methods in social media-based signal detection","volume":"28","author":"Gavrielov-Yusim","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"2","key":"R145","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1002\/jhrm.21237","article-title":"Electronic approaches to making sense of the text in the adverse event reporting system","volume":"36","author":"Benin","journal-title":"J Healthc Risk Manag"},{"key":"R146","doi-asserted-by":"publisher","DOI":"10.3233\/SHTI200375","article-title":"Classification of the severity of adverse drugs reactions","volume":"270","author":"Chauvet","journal-title":"Stud Health Technol Inform"},{"issue":"9","key":"R147","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1007\/s40264-019-00831-4","article-title":"Enabling data-driven clinical quality assurance: predicting adverse event reporting in clinical trials using machine learning","volume":"42","author":"M\u00e9nard","journal-title":"Drug Saf"},{"issue":"3","key":"R148","doi-asserted-by":"publisher","DOI":"10.2196\/11990","article-title":"Detecting hypoglycemia incidents reported in patients\u2019 secure messages: using cost-sensitive learning and oversampling to reduce data imbalance","volume":"21","author":"Chen","journal-title":"J Med Internet Res"},{"key":"R149","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2018.01010","article-title":"Propensity score-based approaches in high dimension for pharmacovigilance signal detection: an empirical comparison on the French spontaneous reporting database","volume":"9","author":"Courtois","journal-title":"Front Pharmacol"},{"issue":"10","key":"R150","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1093\/jamia\/ocy097","article-title":"A chronological pharmacovigilance network analytics approach for predicting adverse drug events","volume":"25","author":"Davazdahemami","journal-title":"J Am Med Inform Assoc"},{"issue":"1","key":"R151","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1097\/PTS.0000000000000104","article-title":"Screening electronic health record-related patient safety reports using machine learning","volume":"13","author":"Marella","journal-title":"J Patient Saf"},{"issue":"11","key":"R152","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.22836","article-title":"Development and validation of a deep learning model for detection of allergic reactions using safety event reports across hospitals","volume":"3","author":"Yang","journal-title":"JAMA Netw Open"},{"key":"R153","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbi.2015.09.015","article-title":"Text mining for pharmacovigilance: using machine learning for drug name recognition and drug-drug interaction extraction and classification","volume":"58","author":"Ben Abacha","journal-title":"J Biomed Inform"},{"key":"R154","doi-asserted-by":"publisher","DOI":"10.3233\/SHTI190180","article-title":"An automated detection system of drug-drug interactions from electronic patient records using big data analytics","volume":"264","author":"Bouzill\u00e9","journal-title":"Stud Health Technol Inform"},{"issue":"5","key":"R155","doi-asserted-by":"publisher","DOI":"10.3390\/ph14050429","article-title":"Cold-start problems in data-driven prediction of drug-drug interaction effects","volume":"14","author":"Dewulf","journal-title":"Pharmaceuticals (Basel)"},{"issue":"7","key":"R156","doi-asserted-by":"publisher","DOI":"10.1016\/j.patter.2020.100108","article-title":"Using machine learning to identify adverse drug effects posing increased risk to women","volume":"1","author":"Chandak","journal-title":"Patterns (N Y)"},{"issue":"4","key":"R157","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1002\/cpt.1789","article-title":"An application of machine learning in pharmacovigilance: estimating likely patient genotype from phenotypical manifestations of fluoropyrimidine toxicity","volume":"107","author":"Correia Pinheiro","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"R158","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/s40264-019-00872-9","article-title":"Complementing observational signals with literature-derived distributed representations for post-marketing drug surveillance","volume":"43","author":"Mower","journal-title":"Drug Saf"},{"key":"R159","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2020.625659","article-title":"Adverse drug reaction discovery using a tumor-biomarker knowledge graph","volume":"11","author":"Wang","journal-title":"Front Genet"},{"issue":"6","key":"R160","doi-asserted-by":"publisher","DOI":"10.1200\/CCI.21.00195","article-title":"Simulating colorectal cancer trials using real-world data","volume":"6","author":"Chen","journal-title":"JCO Clin Cancer Inform"},{"key":"R161","doi-asserted-by":"publisher","DOI":"10.1016\/j.compbiomed.2024.108702","article-title":"Advances in artificial intelligence for drug delivery and development: a comprehensive review","volume":"178","author":"Gholap","journal-title":"Comput Biol Med"},{"issue":"4","key":"R162","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1002\/psp4.12944","article-title":"Computational design of clinical trials using a combination of simulation and the genetic algorithm","volume":"12","author":"Tsuchiwata","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"R163","doi-asserted-by":"publisher","DOI":"10.1016\/j.compbiomed.2023.107441","article-title":"Application of uncertainty quantification to artificial intelligence in healthcare: a review of last decade (2013-2023)","volume":"165","author":"Seoni","journal-title":"Comput Biol Med"},{"issue":"1","key":"R164","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1515\/cdbme-2019-0057","article-title":"Quantifying the uncertainty of deep learning-based computer-aided diagnosis for patient safety","volume":"5","author":"Laves","journal-title":"Curr Dir Biomed Eng"},{"issue":"3","key":"R165","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1016\/j.jval.2021.11.1362","article-title":"Systematic review of health economic evaluations focused on artificial intelligence in healthcare: the tortoise and the cheetah","volume":"25","author":"Voets","journal-title":"Value Health"},{"issue":"3","key":"R166","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1016\/j.jval.2021.11.1360","article-title":"A framework for using real-world data and health outcomes modeling to evaluate machine learning-based risk prediction models","volume":"25","author":"Rodriguez","journal-title":"Value Health"},{"issue":"4","key":"R167","doi-asserted-by":"publisher","DOI":"10.2196\/jmir.5047","article-title":"A patient-centered framework for evaluating digital maturity of health services: a systematic review","volume":"18","author":"Flott","journal-title":"J Med Internet Res"},{"issue":"6 Suppl","key":"R168","doi-asserted-by":"publisher","first-page":"S9","DOI":"10.5694\/mja2.50034","article-title":"Digital health benefits evaluation frameworks: building the evidence to support Australia\u2019s National Digital Health Strategy","volume":"210 Suppl 6","author":"Biggs","journal-title":"Med J Aust"},{"issue":"11","key":"R169","doi-asserted-by":"publisher","DOI":"10.2196\/jmir.8775","article-title":"Beyond adoption: a new framework for theorizing and evaluating nonadoption, abandonment, and challenges to the scale-up, spread, and sustainability of health and care technologies","volume":"19","author":"Greenhalgh","journal-title":"J Med Internet Res"},{"key":"R170","unstructured":"Islam M , editor. Health systems assessment approach: a how-to manual. U.S. Agency for International Development; 2007. URL: https:\/\/cdi.mecon.gob.ar\/bases\/doc\/phr\/publicaciones\/1.pdf [Accessed 14-09-2026]"},{"key":"R171","unstructured":"Everybody\u2019s business \u2013 strengthening health systems to improve health outcomes: WHO\u2019s framework for action. World Health Organization; 2007. URL: https:\/\/iris.who.int\/server\/api\/core\/bitstreams\/809f813f-5b90-4187-861b-3953bb54e244\/content [Accessed 10-09-2026]"},{"key":"R172","unstructured":"Hsiao WC Sparkes SP . A common analytical model for national health systems. Harvard University; 2012."},{"key":"R173","unstructured":"Sparkes S Dur\u00e1n A Kutzin J . A system-wide approach to analysing efficiency across health programmes (health financing guidance no. 2). World Health Organization; 2017. URL: https:\/\/iris.who.int\/server\/api\/core\/bitstreams\/77ec1ed1-e20e-4217-9083-9d6fa8e83cb3\/content [Accessed 10-09-2026]"},{"issue":"6","key":"R174","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines13060646","article-title":"Strengthening national regulatory authorities in Africa: a critical step towards enhancing local manufacturing of vaccines and health products","volume":"13","author":"Duga","journal-title":"Vaccines (Basel)"},{"key":"R175","unstructured":"Ethiopia achieves major milestone in medicines regulation reaching WHO maturity level 3. World Health Organization. 2025. URL: https:\/\/www.who.int\/news\/item\/30-09-2025-ethiopia-achieves-major-milestone-in-medicines-regulation-reaching-who-maturity-level-3 [Accessed 10-09-2026]"},{"key":"R176","unstructured":"Egypt and Nigeria medicines regulators achieve high maturity level in WHO classification and WHO launches list of regulatory authorities that meet international standards. World Health Organization. 2022. URL: https:\/\/www.who.int\/news\/item\/30-03-2022-egypt-and-nigeria-medicines-regulators-achieve-high-maturity-level-in-who-classification-and-who-launches-list-of-regulatory-authorities-that-meet-international-standards [Accessed 10-09-2026]"},{"issue":"10","key":"R177","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1080\/14740338.2023.2251375","article-title":"Drug safety in Africa: a review of systems and resources for pharmacovigilance","volume":"22","author":"Ndagije","journal-title":"Expert Opin Drug Saf"},{"key":"R178","unstructured":"South Sudan poverty and equity brief: October 2025. World Bank Group; 2025. URL: https:\/\/documents1.worldbank.org\/curated\/en\/099450004222541402\/pdf\/IDU-3fe3c1ae-78e2-4a8e-bd36-aa3fc86adc32.pdf [Accessed 10-09-2026]"},{"issue":"2","key":"R179","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1093\/inthealth\/ihae051","article-title":"Accelerating onchocerciasis elimination in humanitarian settings: lessons from South Sudan","volume":"17","author":"Siewe Fodjo","journal-title":"Int Health"},{"issue":"5","key":"R180","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0011320","article-title":"Onchocerciasis-associated epilepsy in Maridi, South Sudan: modelling and exploring the impact of control measures against river blindness","volume":"17","author":"Bhattacharyya","journal-title":"PLoS Negl Trop Dis"},{"issue":"1","key":"R181","doi-asserted-by":"publisher","DOI":"10.1186\/1475-2875-12-374","article-title":"Malaria control in South Sudan, 2006-2013: strategies, progress and challenges","volume":"12","author":"Pasquale","journal-title":"Malar J"},{"key":"R182","unstructured":"Connecting care: Starlink boosting health service delivery in South Sudan. World Health Organization; 2025. URL: https:\/\/www.afro.who.int\/sites\/default\/files\/2025-09\/Knowledge%20Management%20Series%20for%20Health%20-%20Connecting%20care%20Starlink%20boosting%20health%20service%20delivery%20in%20South%20Sudan.pdf [Accessed 10-09-2026]"},{"key":"R183","unstructured":"South Sudan consumes counterfeit drugs banned across Africa \u2013 pharmacist. Africa Press. 2024. URL: https:\/\/www.africa-press.net\/south-sudan\/all-news\/south-sudan-consumes-counterfeit-drugs-banned-across-africa-pharmacist [Accessed 17-09-2026]"},{"key":"R184","unstructured":"Govt probes claims that South Sudan imports banned drugs \u2013 MoH. Africa Press. 2024. URL: https:\/\/www.africa-press.net\/south-sudan\/all-news\/govt-probes-claims-that-south-sudan-imports-banned-drugs-moh [Accessed 17-09-2026]"},{"key":"R185","unstructured":"Ratka JB Njeakor N Nguegan N . Pioneering change: how digital tools are reaching the last mile in South Sudan\u2019s health system. UNICEF South Sudan. 2025. URL: https:\/\/www.unicef.org\/southsudan\/stories\/pioneering-change-how-digital-tools-are-reaching-last-mile-south-sudans-health-system [Accessed 10-09-2026]"},{"issue":"1","key":"R186","doi-asserted-by":"publisher","DOI":"10.1186\/s12936-024-05092-w","article-title":"Usability of a digital tool to support long-lasting insecticide net distribution in Northern Bahr el Ghazal State, South Sudan","volume":"23","author":"Khan","journal-title":"Malar J"},{"key":"R187","unstructured":"Limited delivery and return locations in select markets. Starlink. 2025. URL: https:\/\/starlink.com\/gh\/support\/article\/8699de96-4870-e2bc-e0c5-c68a8ba58dc9 [Accessed 10-09-2026]"},{"issue":"2","key":"R188","first-page":"89","volume":"18","author":"Cherian","journal-title":"South Sudan Med J"},{"key":"R189","unstructured":"Digital mobile wallet usage as an enabler for financial inclusion: UNDP South Sudan report. United Nations Development Programme (UNDP); Feb 24, 2025. URL: https:\/\/www.undp.org\/south-sudan\/publications\/digital-mobile-wallet-usage-enabler-financial-inclusion-undp-south-sudan-report [Accessed 10-09-2026]"},{"issue":"2","key":"R190","doi-asserted-by":"publisher","first-page":"68","DOI":"10.4314\/ssmj.v18i2.4","article-title":"Evaluating the adoption of a mobile application for quality-of-care assessments in South Sudan using Rogers\u2019 innovation diffusion theory","volume":"18","author":"Yugi","journal-title":"South Sudan Med J"},{"key":"R191","doi-asserted-by":"publisher","DOI":"10.1016\/j.evalprogplan.2019.101725","article-title":"Embedding value-for-money in practice: a case study of a health pooled fund programme implemented in conflict-affected South Sudan","volume":"77","author":"Banke-Thomas","journal-title":"Eval Program Plann"},{"key":"R192","unstructured":"Rogers EM . Diffusion of Innovations. 3rd ed. Free Press; 1983. ISBN: 9780029266502"},{"key":"R193","unstructured":"Quality of care manual: indicators, standards, assessments, quality of care application & web interface, operational definitions. Health Pooled Fund; 2021."},{"key":"R194","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/9725741","article-title":"Network security problems and countermeasures of hospital information system after going to the cloud","volume":"2022","author":"Gao","journal-title":"Comput Math Methods Med"},{"key":"R195","volume":"236","author":"Sadoughi","journal-title":"Stud Health Technol Inform"},{"issue":"5","key":"R196","doi-asserted-by":"publisher","first-page":"435","DOI":"10.2217\/pme-2023-0074","article-title":"Cloud-based digital healthcare development for precision medical hospital information system","volume":"20","author":"Oh","journal-title":"Per Med"},{"issue":"9","key":"R197","doi-asserted-by":"publisher","DOI":"10.1007\/s10916-014-0104-3","article-title":"Cloud-based hospital information system as a service for grassroots healthcare institutions","volume":"38","author":"Yao","journal-title":"J Med Syst"},{"issue":"4","key":"R198","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1080\/17441692.2018.1446545","article-title":"Behind the scenes: International NGOs\u2019 influence on reproductive health policy in Malawi and South Sudan","volume":"14","author":"Storeng","journal-title":"Glob Public Health"},{"key":"R199","unstructured":"Independent International Scientific Panel on AI (IISPAI). Preliminary report of the independent international scientific panel on AI: evidence-based assessment of opportunities, risks and impacts of artificial intelligence. United Nations; 2026. URL: https:\/\/www.un.org\/independent-international-scientific-panel-ai\/sites\/default\/files\/2026-07\/en_Preliminary%20Report_.pdf [Accessed 10-09-2026]"}],"container-title":["Journal of Medical Internet Research"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T15:25:23Z","timestamp":1790609123000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jmir.org\/2026\/1\/e96374"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,28]]},"references-count":199,"URL":"https:\/\/doi.org\/10.2196\/96374","relation":{},"ISSN":["1438-8871"],"issn-type":[{"value":"1438-8871","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,28]]},"article-number":"v28i2e96374"}}